Search hospitals > California > Carmichael
Mercy San Juan Medical Center
Claim this profileCarmichael, California 95608
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Adenocarcinoma
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Tumors
90 reported clinical trials
6 medical researchers
Summary
Mercy San Juan Medical Center is a medical facility located in Carmichael, California. This center is recognized for care of Cancer, Breast Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer, Tumors and other specialties. Mercy San Juan Medical Center is involved with conducting 90 clinical trials across 253 conditions. There are 6 research doctors associated with this hospital, such as Shahzad Siddique, Lucian Maidan, MD, Wiley Fowler, MD, and Melissa Lemieux, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage I
Stage II
2Breast Cancer
Global LeaderHER2 negative
Stage IV
ER positive
Top PIs
Shahzad SiddiquePenrose-Saint Francis Healthcare4 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
111 reported clinical trials
176 drugs studied
Lucian Maidan, MDMercy San Juan Medical Center2 years of reported clinical research
Studies Ischemic Stroke
Studies Stroke
4 reported clinical trials
8 drugs studied
Wiley Fowler, MDMercy San Juan Medical Center5 years of reported clinical research
Studies Cervical Cancer
Studies Cancer
3 reported clinical trials
10 drugs studied
Melissa Lemieux, MDMercy Cancer Center - Sacramento6 years of reported clinical research
Studies Prostate Cancer
Studies Adenocarcinoma
2 reported clinical trials
4 drugs studied
Clinical Trials running at Mercy San Juan Medical Center
Breast Cancer
Cancer
Non-Small Cell Lung Cancer
Squamous Cell Carcinoma
Gastric Cancer
Lung Cancer
Multiple Myeloma
Prostate Cancer
Rectal Cancer
Esophageal Cancer
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Mercy San Juan Medical Center?
Mercy San Juan Medical Center is a medical facility located in Carmichael, California. This center is recognized for care of Cancer, Breast Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer, Tumors and other specialties. Mercy San Juan Medical Center is involved with conducting 90 clinical trials across 253 conditions. There are 6 research doctors associated with this hospital, such as Shahzad Siddique, Lucian Maidan, MD, Wiley Fowler, MD, and Melissa Lemieux, MD.